Humasis, Up 5.18% on Rising Theme of COVID-19 (Diagnosis/Treatment/Vaccine Development)

On the 14th, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.62% compared to the previous day, showing strength, while Humasis, a related stock drawing attention, surged by 5.18% compared to the previous day. Humasis is known as an in vitro diagnostic device company.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to provisional data compiled at 10:16, foreigners are net selling 3,000 shares of Humasis, while institutions are net buying 26,000 shares.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)



According to the analysis by Thinkpool Robo Algorithm RASSI, Humasis’s quant financial score is 9.61 points, ranking 16th within the theme. Humasis particularly had a relatively high financial stability score. This means that in terms of financial aspects, Humasis’s ability to respond to changes in the internal and external economic environment is better compared to other stocks within the theme.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of the Robo Algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.